Martin Challand

Martin Challand has a diverse work experience in various fields. Martin started their career at GlaxoSmithKline as a Secondary Manufacturing Technical Support in 2005, where they conducted a successful project on sampling and homogeneity issues in blended raw materials. This project resulted in a permanent change in sampling methods, increasing productivity. During their time at the University of Southampton as a PhD Student from 2006 to 2010, Martin focused on understanding how anaerobic bacteria biosynthesized thiamine pyrophosphate and made critical advances in purification and analysis. At the University of Bristol, they served as a Post-doctoral Research Assistant from 2011 to 2017, contributing to various projects including the development of a novel platform for manufacturing high-value biological molecules and prospecting deep ocean bacteria for new antibiotics. Martin also co-founded Zentraxa in 2017, where they are the Chief Technology Officer responsible for overseeing the company's growth, leading bio-process development and peptide discovery programs, as well as handling business development and fundraising.

Martin Challand completed their education in Chemistry at the University of Southampton. From 2002 to 2006, they pursued their undergraduate studies at the university, earning a Bachelor of Chemistry (MChem) degree. Subsequently, from 2006 to 2010, they furthered their education at the same institution and obtained a Doctor of Philosophy (PhD) degree in Chemistry.